Reporter brief
A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The study does not report results; it describes aims and hypotheses only, so no efficacy claim can be assessed.
- LC3 levels in leukocytes are a surrogate marker with unclear relationship to aging outcomes or clinical longevity.
- The hypothesis links metformin to multiple downstream mechanisms (reduced inflammation, muscle preservation, cardiovascular benefits, neuroprotection) but the study only measured one surrogate outcome; it could not establish which, if any, of these mechanisms occurred.
Study design and sample
Rct; Human.
Adult patients with prediabetes
- Design
- Rct
- Sample
- —
- Journal
- University of New Mexico
- Published
- Dec 11, 2023
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.